Showing 141 - 160 results of 78,611 for search '(( significant amount based ) OR ( significant ((non decrease) OR (a decrease)) ))', query time: 2.46s Refine Results
  1. 141
  2. 142

    Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  3. 143

    Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  4. 144

    Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  5. 145

    Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

    Published 2023
    “…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”
  6. 146

    Data_Sheet_1_A de novo Mutation in the MTUS1 Gene Decreases the Risk of Non-compaction of Ventricular Myocardium via the Rac1/Cdc42 Pathway.pdf by Xuehan Bai (6901679)

    Published 2019
    “…The phosphorylation of Rac1/Cdc42 in the mutation group was significantly lower than in the wild type group.</p><p>Conclusions: A de novo mutation in MTUS1 decreased the stability of microtubules and increased cell polarity via the Rac1/Cdc42 pathway, which may partly elucidate the mechanism underlying cellular protection in NVM.…”
  7. 147

    The number of gauging cross-sections where a statistically significant decreasing trend was identified. by Krzysztof Kochanek (835532)

    Published 2024
    “…<p>The number of gauging cross-sections where a statistically significant decreasing trend was identified.…”
  8. 148
  9. 149
  10. 150
  11. 151

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, visits declined from 10.4 ± 4.5 preoperatively to 7.1 ± 2.2, 3.4 ± 1.3, and 2.6 ± 1.0 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g008" target="_blank">Fig 8</a>).…”
  12. 152
  13. 153
  14. 154
  15. 155

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160